

05 September 2026

To
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Symbol: COHANCE

To
BSE Limited
25th floor, P. J. Towers,
Dalal Street, Mumbai – 400 001

Scrip Code – 543064

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Completion of USFDA Inspection

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we inform you that the United States Food and Drug Administration (USFDA) inspected the Company's formulation (FDF) plant located at Shamshabad, Telangana, from 27 August to 4 September 2026.

The inspection concluded with the issuance of a Form FDA 483 containing four observations. The Company has initiated appropriate corrective and preventive actions (CAPA) and will submit its response within the stipulated timeline.

The Company remains committed to quality and regulatory compliance.

This is for your information and record.

Thank you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(formerly, Suven Pharmaceuticals Limited)

Sisir K Mishra
Company Secretary and Compliance Officer

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSILC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com

